Goldman Sachs
RLMD icon

Goldman Sachs’s Relmada Therapeutics RLMD Stock Holding History

Goldman Sachs’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.87M Buy
699,039
+554,039
+382% +$2.62M ﹤0.01% 3717
2025
Q4 		$700K Buy
+145,000
New +$486K ﹤0.01% 5382
2025
Q2 		– Sell
-120,852
Closed -$32.6K – 6370
2025
Q1 		$32.6K Buy
+120,852
New +$40.1K ﹤0.01% 5919
2024
Q2 		– Sell
-118,243
Closed -$550K – 5877
2024
Q1 		$550K Buy
+118,243
New +$570K ﹤0.01% 4701
2023
Q4 		– Sell
-12,998
Closed -$39K – 5803
2023
Q3 		$39K Sell
12,998
-149,349
-92% -$444K ﹤0.01% 5304
2023
Q2 		$399K Sell
162,347
-37,477
-19% -$104K ﹤0.01% 4855
2023
Q1 		$452K Sell
199,824
-61,885
-24% -$213K ﹤0.01% 4878
2022
Q4 		$913K Buy
261,709
+190,362
+267% +$1.67M ﹤0.01% 4477
2022
Q3 		$2.64M Sell
71,347
-112,827
-61% -$3.13M ﹤0.01% 3725
2022
Q2 		$3.5M Buy
184,174
+154,883
+529% +$3.38M ﹤0.01% 3529
2022
Q1 		$791K Sell
29,291
-54,997
-65% -$1.14M ﹤0.01% 5009
2021
Q4 		$1.9M Sell
84,288
-1,794
-2% -$39.9K ﹤0.01% 4294
2021
Q3 		$2.26M Buy
86,082
+78,637
+1,056% +$2.1M ﹤0.01% 4085
2021
Q2 		$238K Sell
7,445
-3,239
-30% -$113K ﹤0.01% 5655
2021
Q1 		$376K Sell
10,684
-3,401
-24% -$119K ﹤0.01% 5304
2020
Q4 		$452K Buy
+14,085
New +$484K ﹤0.01% 4666
2020
Q2 		– Sell
-106,245
Closed -$3.62M – 5437
2020
Q1 		$3.62M Buy
106,245
+100,832
+1,863% +$4.07M ﹤0.01% 2885
2019
Q4 		$211K Buy
+5,413
New +$164K ﹤0.01% 4870

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs's RLMD Position: Q1 2026 in Review

Goldman Sachs increased its Relmada Therapeutics (RLMD) stake by 382% in Q1 2026, buying an estimated $2.62M and bringing the position to 699,039 shares worth $4.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Goldman Sachs first reported a position in RLMD in Q4 2019 and has held it in 18 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Goldman Sachs held 699,039 shares of Relmada Therapeutics worth $4.87M as of Q1 2026.
  • Goldman Sachs bought 554,039 Relmada Therapeutics shares in Q1 2026, an estimated $2.62M.
  • Relmada Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3717 holding.
  • Goldman Sachs first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.